THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/ --Amgen(NASDAQ: AMGN) today announced results from the Phase 3 OASIZ-301 study of dazodalibep, the only global Phase 3 trial to demonstrate clinically meaningful improvements in systemic disease activity and symptoms in patients with Sjögren's disease. The findings build on positive topline results announced in September and represent an important advance for a disease with noU.S. Food and Drug Administration(FDA)-approved treatments. The full results will be presented during a late-breaking session (LB22) at theAmerican College of Rheumatology (ACR) Convergence2026.
"These Phase 3 results support dazodalibep's potential as a first-in-class treatment for Sjögren's disease and strengthen the clinical rationale for targeting CD40L-mediated immune signaling in these patients," saidJay Bradner, M.D., executive vice president, Research and Development, Artificial Intelligence and Data atAmgen. "In OASIZ-301, improvements in systemic disease activity were observed as early as Week 4 and sustained through Week 48. We look forward to building on these findings as we advance a broader Phase 3 program."
In the randomized, double-blind, placebo-controlled OASIZ-301 study, patients had a mean baseline score of 10.2 on theEuropean Alliance of Associationsfor Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI), which measures systemic disease activity. Both dazodalibep dosing regimens (1,500 mg every four weeks and 3,000 mg every 12 weeks) met the primary endpoint at Week 48, demonstrating statistically significant reductions in systemic disease activity compared with placebo, as measured by the ESSDAI score. The 1,500 mg every four weeks regimen (n=217) showed a least-squares mean reduction of 5.6 points from baseline in ESSDAI score, compared with 3.8 points for placebo (difference of 1.8 points; adjusted p<0.001). The 3,000 mg every 12 weeks regimen (n=217) showed a reduction of 5.2 points, compared with 3.8 points for placebo (difference of 1.4 points; adjusted p=0.010). A treatment effect with dazodalibep was observed as early as Week 4 and sustained through Week 48.
At Week 48, dazodalibep 1,500 mg every four weeks also significantly improved patient-reported dryness, a debilitating symptom of Sjögren's disease, compared with placebo. The placebo-adjusted least-squares mean differences in change from baseline were −1.17 points on the dryness domain of the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and −0.93 points on the dryness domain of the Diary for Assessing Sjögren's Patient Reported Index (DASPRI) (adjusted p<0.001 for both).
"Sjögren's disease is complex and heterogeneous. People may experience dry eyes and mouth, fatigue and joint pain, as well as systemic manifestations affecting organs such as the lungs, kidneys or nervous system, underscoring the complexity of recognizing and managing the disease," said Ghaith Noaiseh, M.D., associate professor of Medicine at theUniversity of Kansas Medical Centerand lead investigator of the study. "In OASIZ-301, both dosing regimens reduced systemic disease activity compared with placebo, and the every four weeks regimen also improved patient-reported dryness. These results are encouraging and represent important progress in our effort to better address patients' unmet needs."
The ACR presentation will also include additional OASIZ-301 analyses of systemic disease activity, patient-reported outcomes and oral dryness, including:
-
At Week 48, greater proportions of patients receiving dazodalibep achieved clinically meaningful reductions of at least 3, 5 or 7 points on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) compared with placebo. These responder analyses show how many patients reached different levels of improvement in systemic disease activity and complement the average ESSDAI change.
-
Over 48 weeks, total ESSPRI and DASPRI scores favored dazodalibep over placebo. Mean improvement in total ESSPRI exceeded 1.5 points with both dosing regimens, consistent with clinically meaningful improvement.
-
Dazodalibep showed consistent improvement in ESSDAI domain-level responses at Week 48. These domains reflect some of the most common systemic manifestations, including constitutional, glandular, articular, lymphadenopathy, cutaneous, and biological.
-
A greater proportion of patients receiving dazodalibep than placebo met the STAR response criteria at Week 48, a composite assessment that considers both patient-reported symptoms and objective measures of disease activity.
-
Patients treated with dazodalibep showed greater increases in stimulated salivary flow, an objective measure of oral dryness, compared with placebo.
"For people living with Sjögren's disease, the need for new treatment options is significant, particularly given the wide-ranging and often debilitating impact of this disease," saidJanet Church, president and chief executive officer, Sjögren's Foundation. "For our community, continued progress in research is important. The Sjögren's Foundation is encouraged by the momentum in Sjögren's research and hopeful that ongoing clinical development will lead to new treatment options that can help address the diverse needs of people living with Sjögren's disease."
The most common adverse events (≥ 5% incidence, reported at a higher rate in dazodalibep compared with placebo) were nasopharyngitis, urinary tract infection, hypertension, and infusion-related reactions, and were generally mild to moderate in nature. Serious adverse events and discontinuations due to adverse events were balanced across all three treatment groups. No imbalance in the incidence of thromboembolic events or opportunistic infections was observed across treatment groups, and malignancy rates were low and comparable across groups.
About Dazodalibep
Dazodalibep is a potential first-in-class CD40L antagonist fusion protein that is designed to target immune activation by disrupting interactions between T cells, glandular epithelial cells, B cells and other antigen-presenting cells. Dazodalibep is being studied in two Sjögren's disease patient groups: those with moderate-to-severe systemic disease and those with high symptom burden and low systemic disease who suffer from dryness, fatigue, and/or pain that profoundly impact daily life.
About OASIZ-301 and the Dazodalibep Development Program
OASIZ-301 is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dazodalibep in patients with Sjögren's disease with moderate-to-severe systemic disease activity (ESSDAI ≥ 5) (n=648). The primary endpoint of the study is change from baseline in ESSDAI score at Week 48.
Key secondary endpoints evaluated dryness, tender and swollen joints, fatigue, and ESSDAI[5] response, defined as a decrease of at least 5 points from baseline.
Additionally,Amgenis conducting OASIZ-303, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of dazodalibep in patients with high symptom burden with low systemic Sjögren's disease activity.Amgenis also conducting OASIZ-304, an open-label, long-term extension study evaluating the long-term safety and tolerability of dazodalibep in eligible participants from OASIZ-301 and OASIZ-303.
About Sjögren's Disease
Sjögren's disease (SjD) is a heterogeneous autoimmune disease, where patients can experience persistent dryness, fatigue, and pain, often alongside systemic involvement that can be progressive. Although SjD is the second most common autoimmune rheumatic disease, it remains widely underrecognized, with the full extent of its systemic severity and debilitating symptomatic impact on patients' lives often underestimated. Despite this burden, there are currently no approved therapies for SjD, and many patients continue to experience persistent systemic disease activity and debilitating symptoms.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.
More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.
Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.